Kenko.com Establishes Joint Venture Company and Opens e-Commerce Site in Mainland China Together with a Chinese …

Posted: Published on September 6th, 2012

This post was added by Dr P. Richardson

TOKYO--(BUSINESSWIRE)-- Kenko.com, Inc. (TOKYO:3325)(CEO: Genri Goto, URL: http://www.kenko.com), a Japanese e-commerce company that sells nutritional supplements, pharmaceutical products, and many other items via the Internet, established the joint venture company LBX UCOM Co., Ltd. together with the major Chinese drugstore chain LBX Pharmacy Chain Co., Ltd. (President:Xie Zilong), and on August 24, 2012, the new company opened an Internet shopping site known as IBALE (URL: http://www.ibale.com).

IBALE is an e-commerce site selling Chinese and Japanese health-related products to the Chinese market. Deploying the e-commerce knowhow and operation efficiency cultivated by Kenko.com and utilizing the brand image and on-line retail licenses (for pharmaceutical products, etc.) of the LBX Pharmacy Chain, the goal is to create a highly convenient site where people can buy all the health products of both China and Japan including pharmaceuticals.

Inheriting Kenko.com's long-tail philosophy, the new company will enrich the site's product lines via the direct import of high-quality Japanese products, and it also plans to engage in wholesales business centered on Japanese products to the Chinese market.

IBALE e-commerce site profile

http://www.ibale.com

Joint venture company profile

LBX Pharmacy Chain Co., Ltd. profile

Kenko.com, Inc. profile (http://www.kenko.com) Kenko.com, Inc. has been operating the Kenko.com e-commerce site selling health-related products since May 2000, with its SKUs totaling more than 180,000 (as of September 2012). It was listed on the Tokyo Stock Exchange Mothers Section in June 2004.

See the original post:
Kenko.com Establishes Joint Venture Company and Opens e-Commerce Site in Mainland China Together with a Chinese ...

Related Posts
This entry was posted in Wholesale Pharmacy. Bookmark the permalink.

Comments are closed.